Unicancer

This study tests a drug called zanidatamab in adults with certain advanced cancers (lung, colorectal, head and neck, sarcoma, or endometrial) that have a specific change in the HER2 gene. The goal is to see if the drug can shrink tumors. Participants receive the drug by IV every …

This study tests whether a new drug called ivonescimab works better than standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has worsened after initial treatment. About 72 participants who were part of a prior trial (SAFIR-ABC10) will be randomly assigne…

This study tests whether injecting two immunotherapy drugs (ipilimumab and nivolumab) directly into melanoma tumors before surgery can destroy more cancer cells and cause fewer side effects than standard treatment. About 50 adults with stage III melanoma that can be surgically re…

This study tests giving immunotherapy before surgery for cancers that haven't spread. The goal is to shrink tumors, boost the immune system, and lower the chance of cancer coming back. About 200 participants will receive treatments matched to their unique immune and tumor profile…

This study tests whether adding the immunotherapy drug pembrolizumab to the chemotherapy drug capecitabine after surgery can help prevent triple-negative breast cancer from coming back. It is for people whose cancer still had some tumor left after initial chemo and immunotherapy.…

This study tests whether adding the drug ivonescimab to standard chemotherapy helps shrink tumors in people with advanced stomach or esophageal cancer. About 88 participants will receive treatment every two weeks. The main goal is to see if more patients respond to the combinatio…

This study looks at whether some women with early-stage triple-negative breast cancer can safely receive less chemotherapy. It uses a marker called TILs (tumor-infiltrating lymphocytes) to decide who might need only the immunotherapy drug pembrolizumab plus a short course of chem…

This study tests whether giving a targeted therapy after initial chemotherapy can help people with advanced biliary cancer live longer without their disease getting worse. About 800 participants will first have their tumor genetically tested. Those with a targetable change and st…

This study tests whether a combination of two oral drugs (tucatinib and capecitabine) plus a chemotherapy given directly into the spinal fluid (intrathecal trastuzumab) can help people with HER2-positive breast cancer that has spread to the lining of the brain and spinal cord. Ab…

This study tests whether adding darolutamide to standard hormone therapy (ADT) can help men with metastatic prostate cancer who are too frail for stronger treatments. About 300 participants will receive either the drug combination or a placebo. The goal is to see if the combinati…

This study tests whether adding a liver-directed chemotherapy (GEMOX) to a standard immunotherapy combination (durvalumab + tremelimumab) works better than immunotherapy alone for people with advanced liver cancer that has a high tumor burden. About 196 adults with liver cancer t…

This study tests lower doses of chemotherapy for people with digestive cancers who have a DPD deficiency, which puts them at high risk for severe side effects. Researchers will monitor 400 participants to find the safest dose that still fights the cancer. The goal is to reduce da…

This study tests whether the immunotherapy drug dostarlimab works better than standard chemotherapy as the first treatment for people with advanced cancers that have specific genetic markers (dMMR/MSI). The cancers studied are rare types like pancreatic, stomach, and small bowel …

This study tests a different chemotherapy drug (trifluridine/tipiracil) for people with metastatic colorectal or gastroesophageal cancer who have a genetic condition (DPD deficiency) that makes standard chemo very toxic. About 73 participants will receive this drug along with oth…

This study tests whether the drug ribociclib can safely replace chemotherapy for women with a common type of early breast cancer (HR+ HER2-) that has an intermediate risk of coming back. About 3,900 participants will receive either standard chemotherapy followed by hormone therap…

This study looks at whether an online program can help women at higher-than-average risk of breast cancer adopt healthier habits, like better diet and more exercise, to lower their risk. About 1,500 women from a larger European screening study will be invited to try the program. …

This study tests whether a digital platform called CUREETY TECHCARE can improve quality of life and reduce hospital visits for people with metastatic triple-negative breast cancer starting their first treatment. About 472 participants will either use the app to report symptoms an…

This study looks at whether a blood test that measures HPV DNA can help find throat cancer recurrence earlier in patients with HPV-related oropharyngeal cancer. About 420 adults who have finished treatment and are cancer-free at 3 months will be followed. The goal is to see if th…

This study looks at whether an artificial intelligence (AI) tool can help predict the risk of arm lymphedema (swelling) after breast cancer radiation therapy. About 724 women with breast cancer will be split into two groups: one where the AI risk is shared with the patient and do…

This study enrolls 400 adults with advanced breast, stomach, bladder, or lung cancer who are receiving a type of targeted therapy called an antibody-drug conjugate (ADC). Researchers will compare tumor samples taken before and after treatment to identify genetic or molecular chan…

This study gathers medical information and biological samples from 400 adults with metastatic colorectal cancer that has a specific genetic change called BRAFV600E. The goal is to learn how this cancer is treated in real-world settings and how long people live. No new treatments …